ClinicalTrials.gg
Not yet recruitingNCT07482540Updated Mar 19, 2026

Role of Dexmedatomidine Drug in Prevention of Atrial Fibrillations Post Mitral Valve Surgery

An interventional study of Dexmedetomidine and Saline in New Onset and Atrial Fibrillation, sponsored by Ain Shams University. Not yet recruiting. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-03-19.

Sponsored by Ain Shams University · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Atrial Fibrillation by Ain Shams University — 3 open to participants now, 4 under way, none of them phase 3. Atrial Fibrillation · Ain Shams University.

Started
2026
with 1 other
No phase
3 of 11
2 open now
Registered
10th of 11
by date

Among the 11 studies in Atrial Fibrillation by Ain Shams University, this one is one of 2 that started in 2026, is one of 3 with no phase, and was the 10th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

3 of the 11 studies in Atrial Fibrillation by Ain Shams University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Atrial Fibrillation by Ain Shams University, or all of them as a file.
02

Study summary

Recently, dexmedetomidine has been suggested as an alternative agent for sedation in tachyarrhythmias due to its antiarrhythmic properties through decreased catecholamine release, prolonged refractory period, and increased vagal tone. In addition, dexmedetomidine is a highly selective agonist that does not interact with the gamma-aminobutyric acid (GABA) receptors. Thus, its analgesic properties are opioid sparing, which is unique among traditional ICU sedatives and avoids the issue of respiratory depression with over-sedation.

Our aim: To evaluate the potential prophylactic effect of perioperative dexmedetomidine in reducing the incidence of early postoperative new onset atrial fibrillation following mitral valve surgery.

03

Conditions studied

  • New Onset
  • Atrial Fibrillation

Browse trials for

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Adult patients aged 21 years or older. (ASA) physical status II-III. Patients able to provide written .

Exclusion criteria

Exclusion Criteria:

History of cardiac arrhythmias: atrial fibrillation or any other cardiac tachyarrhythmias.

Any degree of atrioventricular block or presence of permanent pacemaker and bradycardia (heart rate \< 60 beats/min) or hemodynamic instability.

Emergency mitral valve surgery. Left ventricular dysfunction ( \< 55%) Ischemic heart disease patients. Severe hepatic or renal impairment. Known or to dexmedetomidine. Chronic use of class I or class III anti-arrhythmic drugs

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
140 participants (estimated)

Study arms

  • Active comparator
    Dexmedetomidine

    Drug: Dexmedetomidine

  • Placebo comparator
    Placebo

    Other: Saline

Interventions

  • Drug infusion to reduce postoperative atrial fibrillation

  • OtherSaline

    Normal saline infusion for placebo

06

What researchers measure

Primary outcomes

  1. Incidence rate of post operative new onset atrial fibrillation

    Time frame: 72 hours postoperatively

Secondary outcomes

  1. Any other cardiac tachy-arrhythmias as supra-ventricular or ventricular tachycardia.

    Time frame: 72 hours postoperatively

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Rezaei Y, Peighambari MM, Naghshbandi S, Samiei N, Ghavidel AA, Dehghani MR, Haghjoo M, Hosseini S. Postoperative Atrial Fibrillation Following Cardiac Surgery: From Pathogenesis to Potential Therapies. Am J Cardiovasc Drugs. 2020 Feb;20(1):19-49. doi: 10.1007/s40256-019-00365-1. PubMed 31502217 ↗
  • Greenberg JW, Lancaster TS, Schuessler RB, Melby SJ. Postoperative atrial fibrillation following cardiac surgery: a persistent complication. Eur J Cardiothorac Surg. 2017 Oct 1;52(4):665-672. doi: 10.1093/ejcts/ezx039. PubMed 28369234 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for May 2027, 11 months later.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 11 months is below that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2026
First posted
Mar 19, 2026
StartEst.
Jun 1, 2026
Primary completionEst.
May 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Mar 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07482540
Responsible party
Sponsor
First posted
Mar 19, 2026
Start date
Jun 1, 2026 (estimated)
Primary completion
May 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Mar 19, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmedetomidine

Start the discussion